Supplementary Table 2. Pain Relief by Timepoint (mITT Population): ACHIEVE I and ACHIEVE II

	ACHIEVE I						ACHIEVE II					
	Placebo	Ubrogepant 50 mg			Ubrogepant 100 mg			Placebo	Ubrogepant 25 mg			Ubrogepant 50 mg		
Hours Post Dose	n/N1	n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value	n/N1	n/N1	Odds Ratio (95% CI)	P-value	n/N1	Odds Ratio (95% CI)	P-value
0.5	78/432	70/398	0.98 (0.68, 1.41)	0.8944	67/419	0.82 (0.57, 1.18)	0.2861	97/429	78/399	0.80 (0.57, 1.13)	0.2086	90/434	0.83 (0.6, 1.16)	0.2763
1	160/449	165/408	1.27 (0.96, 1.70)	0.0979	173/437	1.17 (0.88, 1.55)	0.2801	167/443	172/415	1.16 (0.87, 155)	0.3001	204/451	1.30 (0.99, 1.72)	0.0629
1.5	200/450	216/416	1.41 (1.07, 1.85)	0.0161	231/444	1.36 (1.03, 1.78)	0.0277	204/449	216/423	1.24 (0.94, 1.64)	0.1278	250/456	1.40 (1.06, 1.84)	0.0161
2	224/456	256/422	1.69 (1.28, 2.23)	0.0002	275/448	1.69 (1.28, 2.21)	0.0002	220/456	263/435	1.65 (1.25, 2.17)	0.0004	291/464	1.77 (1.35, 2.32)	<0.0001
3	259/456	300/422	2.00 (1.50, 2.68)	<0.0001	338/448	2.44 (1.82, 3.28)	<0.0001	269/456	313/435	1.79 (1.34, 2.38)	<0.0001	348/464	2.06 (1.54, 2.75)	<0.0001
4	298/456	344/422	2.44 (1.78, 3.36)	<0.0001	382/448	3.14 (2.26, 4.36)	<0.0001	301/456	354/435	2.27 (1.65, 3.12)	<0.0001	379/464	2.27 (1.66, 3.11)	<0.0001
6	341/456	268/422	2.43 (1.69, 3.49)	<0.0001	402/448	3.03 (2.08, 4.43)	<0.0001	341/456	380/435	2.33 (1.63, 3.34)	<0.0001	413/464	2.71 (1.88, 3.90)	<0.0001
8	376/456	383/422	2.16 (1.43, 3.27)	0.0003	415/448	2.74 (1.77, 4.22)	<0.0001	371/456	392/435	2.09 (1.40, 3.11)	0.0003	429/464	2.74 (1.80, 4.19)	<0.0001
24	419/456	395/422	1.35 (0.80, 2.27)	0.2595	428/448	1.89 (1.08, 3.32)	0.0264	420/456	411/435	1.45 (0.84, 2.47)	0.1790	444/464	1.84 (1.05, 3.24)	0.0345
48	425/456	401/422	1.40 (0.79, 2.48)	0.2497	427/448	1.49 (0.84, 2.63)	0.1755	425/456	404/435	0.93 (0.55, 1.56)	0.7839	449/464	2.11 (1.12, 3.97)	0.0212

N1 = Number of patients with non-missing postdose pain severity assessment at or prior to the timepoint in the modified intent-to-treat population.
Missing data was handled using last observation carried forward.
Includes data from all participants, including those who took rescue medication or an optional second dose of trial treatment.
Odds ratio (95% CI) and p-value are based on logistic regression with treatment group, historical triptan response, use of medication for migraine prevention, and baseline headache severity as explanatory variables.
Percentages calculated as 100 x (n/N1).